首页 产品中心
  • Dabrafenib Mesylate

    • Dabrafenib Mesylate (GSK 2118436B);GSK-2118436 Mesylate; GSK2118436 Mesylate; GSK 2118436 Mesylate
    货号: abs810452
    CAS号: 1195768-06-9
    分子式: C24H24F3N5O5S3
    分子量: 615.67
    产品说明书
    分享:
    货号-规格 货期 价格 数量
    abs810452-5mg 1-2周 ¥789.00
    - +
    abs810452-10mg 1-2周 ¥1031.00
    - +
    abs810452-50mg 1-2周 ¥2305.00
    - +
    abs810452-100mg 1-2周 ¥3518.00
    - +
    大包装询价
    产品描述
    描述
    Dabrafenib is an orally bioavailable inhibitor of B-raf (BRAF) protein with potential antineoplastic activity.
    纯度
    >98%
    储存/保存方法
    Store at -20℃ for one year(Powder);Store at 2-4℃ for two weeks;Store at -20℃ for six months after dissolution.
    基本信息
    别名
    Dabrafenib Mesylate (GSK 2118436B);GSK-2118436 Mesylate; GSK2118436 Mesylate; GSK 2118436 Mesylate
    外观
    Powder
    可溶性/溶解性
    DMSO: ≥ 36 mg/mL
    生物活性
    靶点
    B-Raf (V600E) ,B-Raf ,C-Raf
    In vitro(体外研究)
    Dabrafenib displayed compelling inhibitory activity in enzyme and cellular mechanistic assays, and in cell proliferation assays in B-RafV600E-driven melanoma lines, SKMEL28 and A375P F11 (IC50 = 3 and 8 nM, respectively), and colorectal carcinoma line Colo205 (IC50 = 7 nM). Dabrafenib has a minimal effect in vitro on cells with wild-type B-Raf (HFF IC50 = 3.0 μM) and in tumor cells not harboring the activating B-RafV600E mutation. It is highly selective, exhibiting >500-fold selectivity for B-RafV600E compared to most kinases screened. Significant activity (. Cellular inhibition of BRAFV600E kinase activity by dabrafenib resulted in decreased MEK and ERK phosphorylation and inhibition of cell proliferation through an initial G1 cell cycle arrest, followed by cell death.
    In vivo(体内研究)
    In a BRAFV600E-containing xenograft model of human melanoma, orally administered dabrafenib inhibited ERK activation, downregulated Ki67, and upregulated p27, leading to tumor growth inhibition. Dabrafenib is orally bioavailable, doesn’t significantly accumulate after multiple dosing, and causes a reduction of pERK that is sustained for up to 18 h post-dosing after 7 and 14 days of dosing.
    温馨提示:本产品仅作科研实验使用,不支持临床等研究
    • 实验方法 实验条件
      0张,还能上传 8 提交
          提示: 尊敬的客户您好,如果您对我们的产品有什么疑问或想要了解的,可以点击“我要提问”按钮填写您的疑问。
          提交不成功?请联系info@absin.cn。
          我要提问

      促销资讯 更多

        订购信息
        您可以从我们的授权经销商处购买absin产品或获得技术支持。若要查看您所在地区的经销商,请从以下的下拉列表中选择。
        GO
        • 0